NCT05585112 is a Phase 1, PHASE2 clinical trial of Lidocaine 2% in Molar Incisor Hypomineralisation, sponsored by Tishreen University.

Who is sponsoring NCT05585112?

NCT05585112 is sponsored by Tishreen University.

What drugs are being tested in NCT05585112?

Interventions in NCT05585112: Lidocaine 2%, Articaine 4%.

What condition does NCT05585112 study?

NCT05585112 studies Molar Incisor Hypomineralisation.

Is NCT05585112 still recruiting?

NCT05585112 is currently completed. Last updated 3 May 2023.

Last reviewed 2023-05-03 · How we verify

NCT05585112

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars

Completed Phase 1, PHASE2 Last updated 3 May 2023

What this trial tests

Phase 1, PHASE2 trial testing Lidocaine 2% in Molar Incisor Hypomineralisation in 26 participants. Completed in 25 December 2022.

Timeline

17 October 2022

Primary endpoint
5 December 2022

25 December 2022

Quick facts

Lead sponsor	Tishreen University
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	26
Start date	17 October 2022
Primary completion	5 December 2022
Estimated completion	25 December 2022
Sites	1 location across Syria

Drugs / interventions tested

Lidocaine 2%
Articaine 4% — full drug profile →

Conditions studied

Molar Incisor Hypomineralisation — all drugs for Molar Incisor Hypomineralisation →

Sponsor

Tishreen University

Who can join

Adults 6 to 12, any sex, with Molar Incisor Hypomineralisation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of injection pain with lidocaine and articaine. Comparison of the efficacy of lidocaine and articaine during treatment of MIH- maxillary molars. Design: A randomized, controlled, crossover, Triple-blinding clinical study including twenty six cooperative children, aged 6-12years old

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lidocaine 2%

Trials testing the same drug.

NCT05928520 — Pain Management in Pediatric Adenotonsillectomy · Phase 3 · unknown
NCT07475520 — Lidocaine IV Injection With Different Doses for Patients With Neuropathic Pain After Mastectomy · NA · completed
NCT05200884 — Local Anesthesia With Lidocaine or Articaine for Molars Affected by MIH · Phase 1, PHASE2 · completed
NCT04609865 — Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia · Phase 3 · terminated
NCT04167176 — Comparison of Analgesic Efficacy of US Guided ESP Block With Port Site Infiltration Following Laparoscopic Cholecystecto · NA · completed

Other recruiting trials for Molar Incisor Hypomineralisation

Currently open trials in the same condition.

NCT06641011 — This Study Aims to Evaluate the Effect of Rinsing Off or Blot-drying Silver Fluoride on the Retention of Subsequently-ap · NA · recruiting

Other Tishreen University trials

Trials by the same sponsor.

NCT07350421 — The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN) · NA · not yet recruiting
NCT07270042 — Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection · NA · not yet recruiting
NCT07099261 — A Comparative Clinical Study to Evaluate Crowns Designed by Artificial Intelligence Versus Crowns Designed Traditional D · NA · not yet recruiting
NCT07467759 — Benzydamine for Radiation-Induced Oral Mucositis in Patients Receiving High-Dose Radiotherapy · Phase 4 · completed
NCT07095946 — Effectiveness of Intraligament vs IANB Anesthesia in Children Using Electronic Syringe · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05585112 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tishreen University
Last refreshed: 3 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing